Clinical Profile of Chronic Cluster Headaches in a Regional Headache Center in Japan.
Japanese
calcitonin gene-related peptide
chronic cluster headache
headache disorders
home oxygen therapy
migraine
Journal
Internal medicine (Tokyo, Japan)
ISSN: 1349-7235
Titre abrégé: Intern Med
Pays: Japan
ID NLM: 9204241
Informations de publication
Date de publication:
2023
2023
Historique:
entrez:
15
2
2023
pubmed:
16
2
2023
medline:
18
2
2023
Statut:
ppublish
Résumé
Objective Little is known about the prevalence and characteristics of chronic cluster headache (CCH) in Japan. We therefore characterized the clinical profile of CCH in Japan by surveying patients with CCH who were registered at a Japanese regional headache center. We also reviewed the existing literature for the prevalence and clinical characteristics of CCH reported in various populations. Methods In this single-center retrospective study, we assessed consecutive patients with cluster headache (CH) who visited a regional tertiary headache center between February 2011 and July 2020. They were treated following the Clinical Practice Guideline for Chronic Headache 2013. We compared their demographic characteristics and clinical features according to the CCH onset pattern (primary vs. secondary). Results Of 420 patients with CH, 19 (4.2%) had CCH (9 primary and 10 secondary). The incidence of CCH in Japan is relatively low compared to that in Western countries but is comparable to that in other Asian countries. CCH showed a higher predominance of men than women. Compared to primary CCH, secondary CCH included a higher proportion of current smokers and older patients during clinic visits. Subcutaneous sumatriptan and oxygen inhalation were the most common abortive treatments, and oral prednisolone and verapamil were the most common preventive treatments. Home oxygen therapy was effective in six of seven patients. Only two patients with coexisting migraine received calcitonin gene-related peptide (CGRP)-targeted therapies. Conclusions CCH remains refractory to treatment. Improving treatment outcomes will require maximizing the use of currently available drugs and expanding the use of neuromodulation, nerve block, and CGRP-targeted therapies.
Identifiants
pubmed: 36792216
doi: 10.2169/internalmedicine.9557-22
pmc: PMC10017249
doi:
Substances chimiques
Calcitonin Gene-Related Peptide
JHB2QIZ69Z
Oxygen
S88TT14065
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
519-525Références
Sci Rep. 2019 Apr 25;9(1):6548
pubmed: 31024044
Brain. 1994 Jun;117 ( Pt 3):427-34
pubmed: 7518321
Cephalalgia. 2000 Nov;20(9):826-9
pubmed: 11167912
J Neurol Neurosurg Psychiatry. 2007 Dec;78(12):1354-8
pubmed: 17442761
J Neurol Neurosurg Psychiatry. 2003 Aug;74(8):1123-5
pubmed: 12876249
Headache. 2012 Jan;52(1):99-113
pubmed: 22077141
Nat Rev Neurol. 2010 Oct;6(10):573-82
pubmed: 20820195
Headache. 2018 May;58(5):688-699
pubmed: 29536529
J Headache Pain. 2016 Dec;17(1):88
pubmed: 27670427
Cephalalgia. 2020 Aug;40(9):935-948
pubmed: 32050782
Cephalalgia. 2018 Jan;38(1):1-211
pubmed: 29368949
Cephalalgia. 2011 Apr;31(5):628-33
pubmed: 21278239
J Headache Pain. 2005 Feb;6(1):3-9
pubmed: 16362185
N Engl J Med. 2019 Jul 11;381(2):132-141
pubmed: 31291515
Front Neurol. 2018 Oct 26;9:908
pubmed: 30416482
Neurology. 2002 Feb 12;58(3):354-61
pubmed: 11839832
Cephalalgia. 2012 May;32(7):571-7
pubmed: 22529192
PLoS One. 2019 Nov 20;14(11):e0224407
pubmed: 31747412
Headache. 1997 Oct;37(9):588-9
pubmed: 9385759
Cephalalgia. 2018 Jun;38(7):1286-1295
pubmed: 28906127
Headache. 2006 Sep;46(8):1246-54
pubmed: 16942468
J Headache Pain. 2013 Mar 21;14:27
pubmed: 23574884
Cephalalgia. 2020 Dec;40(14):1574-1584
pubmed: 32806953
Pain. 1995 Feb;60(2):119-123
pubmed: 7540279
PLoS One. 2019 Aug 26;14(8):e0221155
pubmed: 31449536
Cephalalgia. 2004 Aug;24(8):631-8
pubmed: 15265051
Cephalalgia. 1999 Mar;19(2):88-94
pubmed: 10214533
Neurology. 2005 Feb 8;64(3):469-74
pubmed: 15699377
Headache. 2022 Mar;62(3):329-362
pubmed: 35315067